Altered fatty acid metabolism rewires cholangiocarcinoma stemness features.

Cancer stem cells Hepatobiliary tumours Lipid droplets Lipid metabolism Oleic acid Palmitoleic acid triglycerides

Journal

JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 05 08 2023
revised: 26 07 2024
accepted: 30 07 2024
medline: 21 10 2024
pubmed: 21 10 2024
entrez: 21 10 2024
Statut: epublish

Résumé

Among the reprogrammed metabolic pathways described in cancer stem cells, aberrant lipid metabolism has recently drawn increasing attention. Our study explored the contribution of fatty acids (FA) in the regulation of stem-like features in intrahepatic cholangiocarcinoma (iCCA). We previously identified a functional stem-like subset in human iCCA by using a three-dimensional sphere (SPH) model in comparison to parental cells grown as monolayers (MON). In this study, quantification of intracellular free FA and lipidomic analysis (triacylglycerol [TAG] composition, Stem-like SPH showed a superior content of free FA (citric, palmitic, stearic, and oleic acids) and unsaturated TAG. Molecularly, SPH showed upregulation of key metabolic enzymes involved in Altered FA metabolism contributes to the maintenance of a stem-like phenotype in iCCA. FASN inhibition may represent a new approach to interfere with the progression of this deadly disease. Recent evidence indicates that metabolic disorders correlate with an increased susceptibility to intrahepatic cholangiocarcinoma (iCCA). Our investigation emphasises the pivotal involvement of lipid metabolism in the tumour stem cell biology of iCCA, facilitated by the upregulation of crucial enzymes and the mTOR signalling pathway. From a clinical perspective, this underscores the dual role of FASN as both a prognostic indicator and a therapeutic target, suggesting that FASN inhibitors could enhance patient outcomes by diminishing stemness and tumour aggressiveness. These findings pave the way for novel therapeutic strategies for iCCA and shed light on its relationship with metabolic disorders such as diabetes, obesity, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease.

Sections du résumé

Background & Aims UNASSIGNED
Among the reprogrammed metabolic pathways described in cancer stem cells, aberrant lipid metabolism has recently drawn increasing attention. Our study explored the contribution of fatty acids (FA) in the regulation of stem-like features in intrahepatic cholangiocarcinoma (iCCA).
Methods UNASSIGNED
We previously identified a functional stem-like subset in human iCCA by using a three-dimensional sphere (SPH) model in comparison to parental cells grown as monolayers (MON). In this study, quantification of intracellular free FA and lipidomic analysis (triacylglycerol [TAG] composition,
Results UNASSIGNED
Stem-like SPH showed a superior content of free FA (citric, palmitic, stearic, and oleic acids) and unsaturated TAG. Molecularly, SPH showed upregulation of key metabolic enzymes involved in
Conclusion UNASSIGNED
Altered FA metabolism contributes to the maintenance of a stem-like phenotype in iCCA. FASN inhibition may represent a new approach to interfere with the progression of this deadly disease.
Impact and implications UNASSIGNED
Recent evidence indicates that metabolic disorders correlate with an increased susceptibility to intrahepatic cholangiocarcinoma (iCCA). Our investigation emphasises the pivotal involvement of lipid metabolism in the tumour stem cell biology of iCCA, facilitated by the upregulation of crucial enzymes and the mTOR signalling pathway. From a clinical perspective, this underscores the dual role of FASN as both a prognostic indicator and a therapeutic target, suggesting that FASN inhibitors could enhance patient outcomes by diminishing stemness and tumour aggressiveness. These findings pave the way for novel therapeutic strategies for iCCA and shed light on its relationship with metabolic disorders such as diabetes, obesity, metabolic syndrome, and metabolic dysfunction-associated steatotic liver disease.

Identifiants

pubmed: 39430578
doi: 10.1016/j.jhepr.2024.101182
pii: S2589-5559(24)00186-1
pmc: PMC11486925
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101182

Informations de copyright

© 2024 The Author(s).

Auteurs

Giulia Lori (G)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Mirella Pastore (M)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Nadia Navari (N)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Benedetta Piombanti (B)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Richell Booijink (R)

Department of Biomaterial Science and Technology, University of Twente Enschede, The Netherlands.

Elisabetta Rovida (E)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Ignazia Tusa (I)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Monika Lewinska (M)

Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Jesper B Andersen (JB)

Biotech Research and Innovation Centre, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Tiziano Lottini (T)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Annarosa Arcangeli (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Maria Letizia Taddei (ML)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Erica Pranzini (E)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Caterina Mancini (C)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Cecilia Anceschi (C)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Stefania Madiai (S)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Elena Sacco (E)

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.

Stefano Rota (S)

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.

Adriana Trapani (A)

Department of Pharmacy-Drug Sciences, University of Bari, Bari, Italy.

Gennaro Agrimi (G)

Department of Biosciences, Biotechnologies and Environment, University of Bari, Bari, Italy.

Matteo Ramazzotti (M)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Paola Ostano (P)

Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, Biella, Italy.

Caterina Peraldo Neia (C)

Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, Biella, Italy.

Matteo Parri (M)

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

Fabrizia Carli (F)

Institute of Clinical Physiology, National Research Council, CNR, Pisa, Italy.

Silvia Sabatini (S)

Institute of Clinical Physiology, National Research Council, CNR, Pisa, Italy.

Amalia Gastaldelli (A)

Institute of Clinical Physiology, National Research Council, CNR, Pisa, Italy.

Fabio Marra (F)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Chiara Raggi (C)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Classifications MeSH